Global Perspectives on Lymphoma in 2022 and Beyond
Global clinical experts discuss perspectives on current treatment strategies and emerging therapies for lymphomas, including CLL, SLL, FL, T-cell, MZL, MCL, Waldenström macroglobulinemia, and DLBCL.
FACULTY CHAIR
Brad S. Kahl, MD
Washington University School of Medicine, St. Louis, MO, USA
Faculty Members
Matthew Lunning, DO, FACP
University of Nebraska Medical Center, Omaha, NE, USA
John Allan, MD
Weill Cornell Medicine, New York, NY, USA
Peter Martin, MD
Weill Cornell Medicine, New York, NY, USA
Stefan Barta, MD, MS, MRCPCUK
Penn Medicine, London, United Kingdom
Matthew Matasar, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Georg Hess, MD
Johannes Gutenberg University, Mainz, Germany
Pier Luigi Zinzani, MD, PhD
University of Bologna Institute of Hematology and Medical Oncology, Bologna, Italy
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Advances in CLL/SLL
- Role of Fixed-Duration and MRD-Guided Strategies in CLL
- Advances in Follicular Lymphoma
- Advances in T-Cell Lymphoma
- Advances in Marginal Zone Lymphoma
- Advances in DLBCL/Aggressive B-Cell Lymphoma
- Advances in Mantle Cell Lymphoma
- Advances in Waldenström Macroglobulinemia